新生血管性年龄相关性黄斑变性抗VEGF治疗后视网膜下纤维化的发生
Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration.
作者信息
Hwang John C, Del Priore Lucian V, Freund K Bailey, Chang Stanley, Iranmanesh Reza
机构信息
Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY 10032, USA.
出版信息
Ophthalmic Surg Lasers Imaging. 2011 Jan-Feb;42(1):6-11. doi: 10.3928/15428877-20100924-01. Epub 2010 Sep 29.
BACKGROUND AND OBJECTIVE
to describe the development or progression of subfoveal fibrosis after anti-vascular endothelial growth factor (VEGF) therapy in the absence of significant subfoveal hemorrhage in neovascular age-related macular degeneration.
PATIENTS AND METHODS
retrospective case series.
RESULTS
seven eyes of seven patients with neovascular age-related macular degeneration developed subfoveal fibrosis after anti-VEGF therapy in the absence of significant subfoveal hemorrhage. Five of seven patients experienced vision loss of 0.3 logarithm of the minimum angle of resolution units or greater.
CONCLUSION
subfoveal fibrosis may develop or progress in neovascular age-related macular degeneration despite the absence of significant subfoveal hemorrhage and treatment with anti-VEGF. Development of anti-fibrotic therapeutics may be beneficial in reducing the incidence of subretinal fibrosis.
背景与目的
描述在新生血管性年龄相关性黄斑变性患者中，在无明显黄斑中心凹下出血的情况下，抗血管内皮生长因子（VEGF）治疗后黄斑中心凹下纤维化的发生或进展情况。
患者与方法
回顾性病例系列研究。
结果
7例新生血管性年龄相关性黄斑变性患者的7只眼在抗VEGF治疗后，在无明显黄斑中心凹下出血的情况下发生了黄斑中心凹下纤维化。7例患者中有5例视力下降0.3最小分辨角对数单位或更多。
结论
在新生血管性年龄相关性黄斑变性中，尽管无明显黄斑中心凹下出血且接受了抗VEGF治疗，但黄斑中心凹下纤维化仍可能发生或进展。抗纤维化治疗药物的研发可能有助于降低视网膜下纤维化的发生率。
Zotero 插件